4Vote!
Medical News Today (Free subscription) | 26/11/2009
A recent metobolomics study by researchers from Virginia Commonwealth University Medical Center in Richmond found that impaired peroxisomal oxidation of polyunsaturated fatty acids (PUFA) is associated with the progression of nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH). The study also found significantly higher plasma monounsaturated fatty acids in the blood of patients with...
4Vote!
Medical News Today (Free subscription) | 26/11/2009
Researchers from the University of Michigan determined that only 663,000 of the approximately 3.9 million Americans with hepatitis C virus (HCV) infection received antiviral therapy between 2002 and 2007. Treatment rates appear to be declining, in part because only half of the patients know they are infected. If this disturbing trend continues, by 2030 less than 15% of liver-related deaths from HCV...
+Vote!
Medical News Today (Free subscription) | 24/11/2009
Pharmasset, Inc. (Nasdaq: VRUS) announced that the enrollment of Cohort 2, led by its partner Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY), will continue for the remaining 300 genotype 1 and 4 patients in the ongoing phase 2b trial of RG7128, a first-in-class nucleoside analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.
5Vote!
Chymical Ascension (Free subscription) | 09/11/2009
The CV of Janum Moondi "I'm not lazy long term unemployed benefit scum. I'm an enterprising, creative and socially responsible individual seeking a job I can do with my eyes closed and mp3 player in, paying more than £26,000 a year and not full of douchebags who make me want to slit my wrists in less than six months..." Employment History 07.08 - present - Chief whipper snapper of EveryonesHome.org.uk...
3Vote!
The Earth Times Online Newspaper (Free subscription) | 01/11/2009
BOSTON, Nov. 1 -- Schering-Plough Corporation (NYSE: SGP) today reported two data presentations supporting response guided therapy with boceprevir combination therapy in patients with chronic hepatitis C virus (HCV) genotype 1. These retrospective analyses were prese...
4Vote!
Medical News Today (Free subscription) | 29/10/2009
Celsion Corporation (NASDAQ: CLSN) and Yakult Honsha Co., Ltd. (Tokyo: 2267) announced today that the first patient has been enrolled and treated in Japan as part of Celsion's global Phase III ThermoDox HEAT trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer.
3Vote!
Fiercebiotech (Free subscription) | 27/10/2009
Less than two months after its CEO announced plans to jump ship, Ligand Pharmaceuticals announced a deal to buy the struggling La Jolla, CA-based Metabasis ( MBRX ) for only $3.2 million in cash--less net liabilities--and contingency value rights generated from the sale or partnering of its assets. And Ligand committed $8 million to fund its research work on the newly acquired development programs....
3Vote!
Curing Death by Curing Aging (Free subscription) | 23/10/2009
Researchers from Taipei Veterans General Hospital conducted the first study to provide a comprehensive profile of multiple epithelial-mesenchymal transition (EMT) markers and to demonstrate that Snail and Twist, but not Slug, are the major inducers of EMT in HCC. Results of the study are published in the November issue of Hepatology, a journal of the American Association for the Study of Liver Diseases....
3Vote!
Health Care (Free subscription) | 19/10/2009
Research has revealed that non alcoholic fatty liver diseases can be caused by second hand smoking. NAFLD is a very common disease and causes injury to the liver. In the disease fat accumulates in the liver of those who drink less or no alcohol. NAFLD is caused by exposure to second ...
3Vote!
bioethics.com (Free subscription) | 09/10/2009
Scientists at The Medical College of Wisconsin in Milwaukee have successfully produced liver cells from patients’ skin cells opening the possibility of treating a wide range of diseases that affect liver function. (ScienceDaily)
3Vote!
Colorado Life Science Deal Flow (Free subscription) | 06/10/2009
GlobeImmune (Louisville, CO) a clinical-stage company focused on developing targeted immunogens for the treatment of cancer and infectious diseases, has had an abstract (“ GI-5005 Therapeutic Vaccine Plus PEG-IFN/Ribavirin Improves End of Treatment Response at 48 Weeks Versus PEG-IFN/Ribavirin in Naïve Genotype 1 Chronic HCV Patients ”) for their investigational hepatitis C virus product...
3Vote!
SueSpace (Free subscription) | 04/10/2009
If you walk down any busy street, you will see many people. Some may have epilepsy, but unless they are having a seizure, you wouldn't know they had the condition. Some will have asthma, but unless they are wheezing, you wouldn't know about it. Many will have heart disease, kidney failure, liver diseases, arthritis, systemic lupus erythematosus, ME, ulcers, Crohns disease, diverticulitis,
3Vote!
The Earth Times Online Newspaper (Free subscription) | 24/09/2009
ALEXANDRIA, Va., Sept. 24 /PRNewswire/ -- The Liver Meeting(R) is the premier meeting in the science and practice of hepatology, including the latest findings on new drugs, novel treatments, and the results from pilot and multicenter studies. Approximately 10 percent of Ameri...
4Vote!
Medical News Today (Free subscription) | 18/09/2009
On October 1, Terrence Higgins Trust is launching a new six week course for gay men who are living with HIV and Hepatitis C. The group will meet each week from 6.30 - 9.30pm in central London. The course looks at living with both HIV and Hepatitis C, but the primary focus will be on Hepatitis. Issues covered include dealing with the impact of diagnosis, treatment, sex and disclosure and coping emotionally....
4Vote!
Medical News Today (Free subscription) | 16/09/2009
ChemDiv Inc. of San Diego, and iDialog (Intellektualniy Dialog) of Yaroslavl, Russia, announced today the successful completion of a pre-clinical development and the subsequent nomination of ID-12 as lead clinical development candidate for the treatment of chronic hepatitis C. This novel small molecule orally-bioavailable inhibitor of hepatitis C virus (HCV) blocks early stage of viral infection. Vadim...
Videos